Drug candidates for the treatment of Chronic obstructive pulmonary disease (COPD) Severe asthma
Arcede Pharma AB (publ) godkänt för notering på Spotlight Stock Market
BUSINESS CONCEPT
Patent protected drug candidates based on new mode of actions showing promising results in preclinical studies.
STRATEGY
Arcede aims at being an attractive partner for academic research groups, biotech companies and global pharmaceutical companies with expertise positioned all along the drug development path – from academic research to finished product on the market.
VISION
Aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients.
COLLABORATIONS with strategic partners
who assume the financial and operational responsibility for developing the final product.
ARCEDE Pharma – Project Portfolio
RCD405
The drug candidate (RCD405) for the treatment of COPD and severe asthma in preclinical phase, belonging to the RESP9000 project. Additional undisclosed preclinical assets.
Board of Directors and CEO
A competent team with extensive experience in both business development and commercialisation of research findings as well as strong scientific background in relevant areas complemented with knowledge in clinical development and design of clinical trials.
Ingemar Kihlström
Chairman of the Board
PhD in Physiology and Associate Professor, University of Uppsala, Sweden
Chairman of Miris Holding, Ilya Pharma, Spectracure and Prolight Diagnostics. Board member in several pharma and biotech companies
Consultant in bioengineering, banking, and finance since 2004. R&D and business development at Astra and Pharmacia
Johanna Asklin
Board member
PhD in immunology, University of Gothenburg, Sweden
Master of Pharmaceutical Biosciences, University of Gothenburg, Sweden
Leading positions within Business Development, currently Director of Client Partnerships at Saga Diagnostics.
Board assignments in early stage diagnostic and therapeutic companies.
Laurent Pacheco
Board member
PhD in Economics, University of Paris Dauphine, France
Med. Dr., University of Paris La Sorbonne, France
More than 15 years of international experience in healthcare and management consulting
Expertise in Due Diligence, Valuation, Commercial Strategy and Performance Improvement
Åsa Kornfeld
Board member
Master of Science, University of Bordeaux, France
Bachelor of Science in Chemistry and Biology, University of Lund, Sweden
Director and VP positions within Pricing, Reimbursement and Market Access within the pharmaceutical industry, with 25 years of international experience
Mia Lundblad
CEO
PhD in Clinical Pharmacology, Karolinska Institutet, Sweden
Master of Pharmaceutical Sciences, University of Uppsala, Sweden
Previous Principal and Senior Scientist positions within pharmacokinetics and clinical pharmacology, from discovery to early clinical development, at Novo Nordisk and Ferring.
